^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NAV-2729

i
Other names: NAV-2729
Associations
Trials
Company:
Navigen, University of Utah
Drug class:
ARF6 inhibitor
Related drugs:
Associations
Trials
over1year
The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins. (PubMed, J Biol Chem)
Finally, our screens identified 48 other possible targets of NAV-2729. These results illustrate the complexities of defining targets of small molecules and identify NAV-2729 as a model PH domain- binding inhibitor.
Journal
|
ASAP1 (ArfGAP With SH3 Domain)
|
NAV-2729
2years
Pharmacological Inhibition of Lipid Import and Transport Proteins in Ovarian Cancer. (PubMed, Cancers (Basel))
Overall, the small molecule inhibitors of lipid handling proteins BMS309403, HTS01037, NAV2729, SB-FI-26, and sulfosuccinimidyl oleate (SSO) caused a drug-specific, dose-/time-dependent inhibition of FA/LDL uptake, associated with reduced proliferation, cell cycle arrest, and apoptosis. Our findings indicate that OC cells are very sensitive to lipid deficiency. This dependency should be exploited for development of novel strategies against OC.
Journal
|
CD36 (thrombospondin receptor) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
NAV-2729